The Foundation is committed sharing the most accurate information from the world’s leading experts, many from our Global Medical Advisory Board. The COVID-19 situation changes daily and we will continue to share updates that are vetted by the experts in GBS. In addition we are in regular contact with the FDA representing the patient voice in the top-level decision making. We understand that there are many opinions creating confusion so please consider the source of your information before drawing conclusions. As always, all decisions should be made with your personal physician based on your own health. Please continue to check our website for updated information.
In reaction to recent research published in Brain (click here to read more), Professor Lunn has offered this guidance in regards to our community.
A UK based epidemiological study, linked below, has found no causal association between COVID-19 infection and Guillain-Barré syndrome. This means that GBS developing at the same time or close to that of COVID-19 is most likely coincidental.
COVID-19 Ask the Experts with Dr. Ken Gorson, part of our educational series featuring medical experts from the Foundation’s Global Medical Advisory Board.
The National Organization of Rare Disorders (NORD) launched a COVID-19 Critical Relief Program to provide much-needed assistance to members of the rare community affected by the current pandemic. The program provides financial relief that may be utilized to support critical, non-medical needs. The COVID-19 Critical Needs Non-Medical Assistance Fund provides eligible individuals impacted by the…
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
By Dr. David Saperstein Antibodies (also known as immunoglobulins) play an important role in health and illness. Many of you regularly receive intravenous immunoglobulin (IVIG) to treat your autoimmune disease. Flooding a person’s system with antibodies from normal, healthy individuals can reverse problems caused by abnormally overactive immune systems. However, providing antibodies that fight a specific infection can…
The Plasma Protein Therapeutics Association (PPTA) has provided a statement specific to plasma protein therapies in light of the COVID-19 pandemic. CLICK HERE to read the statement. The PPTA notes that their Pathogen Safety Steering Committee continues to monitor the situation and is currently working on a broader update for the community. We will share these…
The coronavirus COVID-19 situation is evolving rapidly. In the interest of concerns and questions that the Foundation is receiving regarding the spread of the coronavirus COVID-19, the GBS|CIDP Global Medical Advisory Boards offers the following statement: GBS, CIDP and variants will not put patients at any higher risk of contracting the COVID-19, but those who…